Study of safety and effects of HTL0009936 in healthy subjects
Research type
Research Study
Full title
A Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of HTL0009936 in Healthy Subjects
IRAS ID
138245
Contact name
Annelize Koch
Contact email
Sponsor organisation
Heptares Therapeutics
Eudract number
2013-002307-34
ISRCTN Number
not provided
Research summary
The new medicine tested in this study is a compound called HTL0009936. Heptares is developing HTL0009936 for treating Alzheimer’s disease. Alzheimer’s disease is an irreversible, progressive brain disease that slowly destroys memory and thinking skills, and eventually even the ability to carry out the simplest tasks. Alzheimer’s disease is the most common cause of dementia among older people.
The study will be performed in 4 different main parts, with each part having its own specific purpose. The main purpose of the study is to determine HTL0009936 safety and tolerability. The study will also look at the levels of HTL0009936 in the blood, urine and cerebrospinal fluid.
HTL0009936 will be administered as single and multiple ascending doses, with and without food as a single dose, and with scopolamine to determine the effects of HTL0009936 on cognitive functions.
This study will recruit healthy males between the ages of 18 and 55 years, and also healthy elderly males and females aged 65 years and older.
REC name
London - Brent Research Ethics Committee
REC reference
13/LO/1575
Date of REC Opinion
18 Nov 2013
REC opinion
Further Information Favourable Opinion